All In Biotech

Drug Trial Radar · NCT03879772

Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)

Dose-Ranging Study of Mometasone Furoate Nasal Spray (SCH 32088) in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (Protocol C95-161)

Last checked: Nov 20, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 679 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

679

Actual

Start

Mar 12, 1996

Primary completion

Jul 1, 1996

Study completion Jul 1, 1996

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Mar 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to identify the lowest dosage of mometasone furoate nasal spray (MFNS) that provided adequate efficacy with an acceptable safety profile for children (ages 6-11) with seasonal allergic rhinitis (SAR). The MFNS dose levels of 25, 100, and 200 mcg QD were compared with beclomethasone dipropionate (BDP), as an active control, and placebo.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

  • Mometasone furoate nasal sprayDrug

    intranasal administration

  • Beclomethasone dipropionate nasal sprayDrug

    intranasal administration

  • Placebo nasal sprayDrug

    intranasal administration

  • Chlorpheniramine maleate syrupDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Total Nasal Symptom Score (TNSS) at Day 8 as Assessed by InvestigatorTime frame: Baseline (Day 1) and Day 8

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.